64Cu-GRIP B in Patients With Advanced Genitourinary Malignancies
Status:
Not yet recruiting
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
This is a first-in-human phase I/II imaging study of 64Cu-GRIP B PET in patients with
advanced genitourinary (GU) malignancies. The tracer is designed to detect extracellular
granzyme B as it is secreted by activated immune cells in the tumor microenvironment, which
may highlight tumors that will regress on treatment with immunomodulatory therapies. The
study population is focused on genitourinary malignancies, including renal cell and
urothelial cancer, two tumor types with high mutational burden and tumor infiltrating
lymphocytes compared to other tumor types, and have a predictable response rate at the
population level to immune checkpoint inhibitors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Rahul Aggarwal
Collaborators:
National Cancer Institute (NCI) U.S. Army Medical Research Acquisition Activity